These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32323152)

  • 21. The Vps35 D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer.
    Follett J; Norwood SJ; Hamilton NA; Mohan M; Kovtun O; Tay S; Zhe Y; Wood SA; Mellick GD; Silburn PA; Collins BM; Bugarcic A; Teasdale RD
    Traffic; 2014 Feb; 15(2):230-44. PubMed ID: 24152121
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vacuolar protein sorting 35 (Vps35) rescues locomotor deficits and shortened lifespan in Drosophila expressing a Parkinson's disease mutant of Leucine-Rich Repeat Kinase 2 (LRRK2).
    Linhart R; Wong SA; Cao J; Tran M; Huynh A; Ardrey C; Park JM; Hsu C; Taha S; Peterson R; Shea S; Kurian J; Venderova K
    Mol Neurodegener; 2014 Jun; 9():23. PubMed ID: 24915984
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contributions of VPS35 Mutations to Parkinson's Disease.
    Rahman AA; Morrison BE
    Neuroscience; 2019 Mar; 401():1-10. PubMed ID: 30660673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of the VPS35 D620N mutation in Parkinson's disease.
    Mohan M; Mellick GD
    Parkinsonism Relat Disord; 2017 Mar; 36():10-18. PubMed ID: 27964832
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endosomal traffic and glutamate synapse activity are increased in VPS35 D620N mutant knock-in mouse neurons, and resistant to LRRK2 kinase inhibition.
    Kadgien CA; Kamesh A; Milnerwood AJ
    Mol Brain; 2021 Sep; 14(1):143. PubMed ID: 34530877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes.
    Wang W; Wang X; Fujioka H; Hoppel C; Whone AL; Caldwell MA; Cullen PJ; Liu J; Zhu X
    Nat Med; 2016 Jan; 22(1):54-63. PubMed ID: 26618722
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons.
    Hanss Z; Larsen SB; Antony P; Mencke P; Massart F; Jarazo J; Schwamborn JC; Barbuti PA; Mellick GD; Krüger R
    Mov Disord; 2021 Mar; 36(3):704-715. PubMed ID: 33142012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deciphering the role of VPS35 in Parkinson's disease.
    Williams ET; Moore DJ
    J Neurosci Res; 2018 Aug; 96(8):1339-1340. PubMed ID: 29775219
    [No Abstract]   [Full Text] [Related]  

  • 29. A conserved retromer sorting motif is essential for mitochondrial DLP1 recycling by VPS35 in Parkinson's disease model.
    Wang W; Ma X; Zhou L; Liu J; Zhu X
    Hum Mol Genet; 2017 Feb; 26(4):781-789. PubMed ID: 28040727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Formation of retromer transport carriers is disrupted by the Parkinson disease-linked Vps35 D620N variant.
    Cui Y; Yang Z; Flores-Rodriguez N; Follett J; Ariotti N; Wall AA; Parton RG; Teasdale RD
    Traffic; 2021 Apr; 22(4):123-136. PubMed ID: 33347683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VPS35 regulates cell surface recycling and signaling of dopamine receptor D1.
    Wang C; Niu M; Zhou Z; Zheng X; Zhang L; Tian Y; Yu X; Bu G; Xu H; Ma Q; Zhang YW
    Neurobiol Aging; 2016 Oct; 46():22-31. PubMed ID: 27460146
    [TBL] [Abstract][Full Text] [Related]  

  • 32. VPS35 mutations in Parkinson disease.
    Vilariño-Güell C; Wider C; Ross OA; Dachsel JC; Kachergus JM; Lincoln SJ; Soto-Ortolaza AI; Cobb SA; Wilhoite GJ; Bacon JA; Behrouz B; Melrose HL; Hentati E; Puschmann A; Evans DM; Conibear E; Wasserman WW; Aasly JO; Burkhard PR; Djaldetti R; Ghika J; Hentati F; Krygowska-Wajs A; Lynch T; Melamed E; Rajput A; Rajput AH; Solida A; Wu RM; Uitti RJ; Wszolek ZK; Vingerhoets F; Farrer MJ
    Am J Hum Genet; 2011 Jul; 89(1):162-7. PubMed ID: 21763482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice.
    Vanan S; Zeng X; Chia SY; Varnäs K; Jiang M; Zhang K; Saw WT; Padmanabhan P; Yu WP; Zhou ZD; Halldin C; Gulyás B; Tan EK; Zeng L
    Mol Brain; 2020 Dec; 13(1):164. PubMed ID: 33261640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenic mutation in VPS35 impairs its protection against MPP(+) cytotoxicity.
    Bi F; Li F; Huang C; Zhou H
    Int J Biol Sci; 2013; 9(2):149-55. PubMed ID: 23411763
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retromer-dependent neurotransmitter receptor trafficking to synapses is altered by the Parkinson's disease VPS35 mutation p.D620N.
    Munsie LN; Milnerwood AJ; Seibler P; Beccano-Kelly DA; Tatarnikov I; Khinda J; Volta M; Kadgien C; Cao LP; Tapia L; Klein C; Farrer MJ
    Hum Mol Genet; 2015 Mar; 24(6):1691-703. PubMed ID: 25416282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased copper toxicity in Saccharomyces cerevisiae lacking VPS35, a component of the retromer and monogenic Parkinson disease gene in humans.
    Sowada N; Stiller B; Kubisch C
    Biochem Biophys Res Commun; 2016 Aug; 476(4):528-533. PubMed ID: 27262440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Parkinson's disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress.
    McCarron KR; Elcocks H; Mortiboys H; Urbé S; Clague MJ
    Biochem J; 2024 Feb; 481(4):265-278. PubMed ID: 38299383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Retromer's Role in Endosomal Trafficking and Impaired Function in Neurodegenerative Diseases.
    Follett J; Bugarcic A; Collins BM; Teasdale RD
    Curr Protein Pept Sci; 2017; 18(7):687-701. PubMed ID: 26965691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation.
    Follett J; Bugarcic A; Yang Z; Ariotti N; Norwood SJ; Collins BM; Parton RG; Teasdale RD
    J Biol Chem; 2016 Aug; 291(35):18283-98. PubMed ID: 27385586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.